Atezolizumab (DrugBank: Atezolizumab)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
85 | 特発性間質性肺炎 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-jRCTs031190084 | 05/09/2019 | 27/08/2019 | TORG1936 / AMBITIOUS study | A phase II study of Atezolizumab for advanced / recurrent Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias - TORG1936 / AMBITIOUS study | Advanced / recurrent Non-small cell lung cancer with idiopathic interstitial pneumonia | Atezolizumab 1200mg, every 3 weeks | KATO Terufumi | IKEDA Satoshi | Suspended | >= 20age old | Not applicable | Both | 38 | Phase 2 | Japan |